Unformatted text preview: ACTIVE LEARNING TEMPLATE: Medication Andreja D. Wilson
MEDICATION___________________________________________________________________________ REVIEW MODULE CHAPTER____________
_____________________________________________________________________ PURPOSE OF MEDICATION Expected Pharmacological Action Potent, locally acting anti-inflammatory and
immune modifier. Therapeutic Use
Nebulization—Maintenance treatment and prophylactic therapy of CF.
Oral inhalation—Chronic control of persistent bronchial constriction.
May decrease requirement for or eliminate use of systemic
corticosteroids over time Complications
CNS: headache.Derm: rash.
EENT: otitis media, dysphonia, epistaxis, oropharyngeal fungal infections, pharyngitis, rhinitis,
sinusitis. Resp: bronchospasm, cough.
GI: abdominal pain, diarrhea, dyspepsia, gastroenteritis, nausea, vomiting. Endo:
adrenal suppression (high dose, long-term therapy only), decreased growth in children,
MS: back pain. Misc: ANAPHYLAXIS, flu-like syndrome. Medication Administration
Inhaln (Adults): — 180– 360 mcg twice daily (not to exceed 720
mcg twice daily).
Inhaln (Children 6 yr): — 180– 360 mcg twice daily (not to
exceed 360 mcg
Respules: Inhaln (Children 1– 8 yr): Previously on
bronchodilators alone– 0.5 mg once
daily or 0.25 mg twice daily (not to exceed 0.5 mg/day);
Previously on otherinhaled
corticosteroids—0.5 mg once daily or 0.25 mg twice daily (not
to exceed 1 mg/
day); Previously on oral corticosteroids—1 mg once daily or 0.5
mg twice daily
(not to exceed 1 mg/day). Contraindications/Precautions Hypersensitivity; Active untreated infections; Diabetes or
glaucoma; Underlying immunosuppression; Systemic
corticosteroid therapy; Interactions
Strong CYP3A4 inhibitors, including ritonavir, atazanavir,
clarithromycin, indinavir, itraconazole, ketoconazole,
nefazodone, nelfinavir,saquinavir, and telithromycin inc.
metabolism and inc. levels of budesonide. Nursing Interventions
-Monitor respiratory status and lung sounds.
-Assess pulmonary function tests periodically
during and after treatment
-Assess patients changing from systemic
corticosteroids to inhalation corticosteroids for
signs of adrenal insufficiency
-Lab Test Considerations: Periodic adrenal
function tests may be ordered to
assess degree of hypothalamic-pituitary-adrenal
(HPA) axis suppression in
chronic therapy. Client Education
Evaluation of Medication Effectiveness Management/ improvement of the symptoms of CF ACTIVE LEARNING TEMPLATES -Advise patient to notify health care professional
if sore throat/mouth/sx of anaphylaxis
-Rinse mouth with water after treatment
-Female patients to notify health care
professional if pregnancy is planned or
suspected or if breast feeding
-Allow at least 1 min between inhalations of med.
Do not shake inhaler or use with spacer.Wait 5
min between use of bronchodilator and use of
corticosteroid Therapeutic Procedure A7 ...
View Full Document